(Q42665424)

4 November 2017

title

Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide (English)

1 reference

4 November 2017

1 reference

Malcolm A Young

1

1 reference

4 November 2017

Jeffrey A Wald

2

1 reference

4 November 2017

Jessica E Matthews

3

1 reference

4 November 2017

Fred Yang

4

1 reference

4 November 2017

Rickey R Reinhardt

5

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 May 2014

1 reference

4 November 2017

published in

Postgraduate Medicine

1 reference

4 November 2017

volume

126

1 reference

4 November 2017

issue

3

1 reference

4 November 2017

page(s)

35-46

1 reference

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Metformin use in chronic kidney disease: new evidence to guide dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Workshop report and follow-up--AAPS Workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples--implications of Crystal City recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Can a reduction in extracellular fluid volume result in increased serum albumin in peritoneal dialysis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Incretin effects on β-cell function, replication, and mass: the human perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Exenatide may aggravate moderate diabetic renal impairment: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Exenatide-associated ischemic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2754

21 January 2018

Identifiers

DOI

10.3810/PGM.2014.05.2754

1 reference

4 November 2017

1 reference